Hepatitis c “revolution” may transform liver cancer outcomes
Michael P. Manns, MD Novel agents that concentrate on the replication from the hepatitis C virus (HCV) are poised to possess a far-reaching effect on the prevention and recurrence of hepatocellular carcinoma (HCC) and also have proven the opportunity to reverse liver fibrosis, including cirrhosis in patients with finish-stage HCC, based on a number one …